Refine by
Biomarker Blood Articles & Analysis
29 news found
BioMark’s blood-based biomarker panel has been selected to define personalized lung cancer risk assessment in Europe’s screen-eligible population who are most likely to benefit from a CT scan. ...
STALICLA’s unique approach addresses a major weakness in the drug development process for NDDs and neuropsychiatric disorders: behaviour is a terrible biomarker. Thanks to DEPI, a proprietary platform aggregating molecular data and human genetic information, STALICLA pushes the frontier of precision medicine further into precision NDDs. ...
BySTALICLA
“MDA is excited to support this work at Iron Horse Diagnostics, with the goal to address one of the most pressing challenges to ALS drug development — the need for prognostic biomarkers,” said MDA Scientific Program Officer Amanda M. Haidet-Phillips, Ph.D. ...
BynVector
And the highest-quality data about our biology comes from our blood. Blood tests are goldmines of health information. Human blood contains hundreds of biomarkers—the molecular signs of health—that not only can identify any underlying or developing health problems but also can help people make more informed decisions ...
” “We also have in-market and pipeline EXO-NET® exosome capture tools for the fast, precise and efficient capture of exosomes from blood and other biofluids. “Exosomes are a rapidly growing research area for biomarker discovery and the diagnosis and treatment of cancer and other ...
(Nasdaq: GH), a leading precision oncology company, and the Vall d’Hebron Institute of Oncology (VHIO), one of Europe’s leading cancer research organizations, today announced that the first blood-based cancer testing services in Europe based on Guardant Health’s industry-leading digital sequencing platform are now available at the VHIO liquid biopsy testing ...
In addition, the clinical improvement was associated with positive impact upon blood biomarkers (e.g. a decrease in muscle atrophy biomarkers and a normalization of metabolic biomarkers). ...
” IsoPSA is a non-invasive, blood-based test that has demonstrated in large, multicenter studies superior diagnostic accuracy and clinical utility when compared to prostate-specific antigen (PSA), the current standard of care in prostate cancer, in men being considered for prostate biopsy. ...
“We expect that IsoPSA, our novel blood-based prostate cancer test, may fundamentally shift the diagnostic paradigm of prostate cancer, and improve patient care and ...
To be part of the EIC Accelerator is a big boost for the company and the commercialization of Amadix’ firs product, PREVECOL® (previously known as Colofast), a test for the early detection of colorectal cancer in blood combining biomarkers and artificial intelligence tools. Read the full new here ...
ByAmadix
OncoDNA, a genomic and theranostic company specializing in precision medicine, and Bergonié Institute, a non-profit private hospital entirely devoted to fighting cancer, today announced a new clinical trial to evaluate the use of comprehensive biomarker testing and liquid biopsy in 700 patients diagnosed with an advanced metastatic cancer. The Appolo study will recruit ...
* Lectin-based development services According to the official speaker from CD BioGlyco, their service can be utilized for vaccine development, detection kit development, virology research, tools development for microarray, immunoassay, and virus purification from whole blood, and development of biomarkers to predict disease severity. ...
In a separate development at CTAD, Suzanne Schindler, M.D., Ph.D., with Washington University School of Medicine, presented data from 1,085 individuals that showed the PrecivityAD™ blood test was highly concordant with CSF biomarkers and amyloid PET status in both cognitively normal (74% of those studied) and cognitively impaired (26%) individuals. The ...
Chagas can also be transmitted congenitally, via consumption of food contaminated by kissing bugs, and by blood transfusion or organ transplantation. Infection can lead to chronic disease lasting decades, with a higher risk of death due to cardiac or digestive system impairment; up to one third of infections result in debilitating symptoms, while the remainder are asymptomatic. ...
Reducing the number of unnecessary biopsies, increasing biopsy yield, and distinguishing high grade disease risk from low grade or benign disease with an effective blood test will be critical to savings lives, costs, and significantly improve overall patient ...
C2N under a technology transfer agreement with Washington University, developed this mass spec assay into the PrecivityAD™ blood test. BioFINDER’s large comparison of blood plasma amyloid-beta assays found that the Washington University assay performed the best out of seven assays, including in the measurement of phosphorylated tau-217, an ...
Its Solvent Interaction Analysis™ (SIA) technology investigates protein biomarkers in general circulation at the structural level (as opposed to overall biomarker concentration in blood), providing better and more direct insights regarding the protein origin on the cellular level, thus improving test specificity to the underlying disease ...
The trial also incorporated our CypCel diagnostic technology as a monitor of small intestinal villous health utilizing the drug biomarker simvastatin as measured in blood samples. Histologic protection was assessed by measuring changes in villous height to crypt death ratio ...
Through our ongoing partnership with QIAGEN, we also plan to develop complementary a biomarker diagnostic test that would enable practitioners to more effectively identify women expected to respond to VGX-3100." Biomarker Development In the course of the REVEAL 1 and REVEAL 2 clinical trials, INOVIO continues to pursue development of a pre-treatment RNA-based ...
Its Solvent Interaction Analysis™ (SIA) technology investigates protein biomarkers at the structural level (as opposed to overall biomarker concentration in blood), providing better and more direct insights regarding the protein biomarker origin on the cellular level, thus improving test specificity to the underlying ...